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Endogenous Galectin-9 Suppresses 
Apoptosis in Human Rheumatoid 
Arthritis Synovial Fibroblasts
Mark J. Pearson1,4, Magdalena A. Bik2, Caroline Ospelt  3, Amy J. Naylor  2,4, 
Corinna Wehmeyer2,4, Simon W. Jones2,4, Christopher D. Buckley  2,4, Steffen Gay3, 
Andrew Filer2,4 & Janet M. Lord2,4
Galectin-9 (Gal9) has been postulated to have anti-inflammatory properties based on the ability of 
exogenous Gal9 to induce apoptosis in synovial fibroblasts in animal models of rheumatoid arthritis 
(RA). Here we aimed to assess the potential role of endogenous Galectins, including Gal9, in the 
inflammatory pathology of the RA synovium in humans. Firstly expression of Galectins 1–9 was 
determined in synovial fibroblasts (RASF) and dermal fibroblasts (DF) isolated from RA patients, the 
latter representing a non-inflamed site. We then further challenged the cells with pro-inflammatory 
TLR agonists and cytokines and assessed Galectin expression. Gal9 was found to be differentially and 
abundantly expressed in RASF compared to DF. Agonists of TLR3 and TLR4, along with IFNgamma were 
also found to induce Gal9 expression in RASF. siRNA was then used to knock-down Gal9 expression 
in RASF and the effects of this on apoptosis and cell viability were assessed. Increased apoptosis was 
observed in RASF following Gal9 knock-down. We conclude that, unlike exogenous Gal9, endogenous 
Gal9 is protective against apoptosis and enhances synovial fibroblast viability suggesting that its role in 
RA is both pathogenic and pro-inflammatory.
Rheumatoid arthritis (RA) is a chronic inflammatory disease which leads to destruction of the joint and expan-
sion of the synovial membrane leading to an “activated” synovial membrane. Multiple cell types are recruited 
to the inflammatory milieu which develops within the normally acellular synovium. Although the exact mech-
anisms driving the onset and maintenance of inflammation in RA are still being determined, it is known that 
fibroblasts, macrophages and pro-inflammatory B and T cell populations significantly contribute to RA disease 
pathology1–6 including IL-6, IL-23p19, CCL-20, and GM-CSF7–9. Their presence within the RA synovium is thus 
thought to be an important driver of the chronicity of inflammation1,10–12.
Galectins are an evolutionarily conserved family of immunomodulatory animal lectins which are expressed 
in a number of immune cell populations including macrophages, T cells and fibroblasts13. Eleven galectins have 
been described in humans and they have a broad range of actions14. In addition, several galectins have been 
implicated in the regulation of cell death, notably galectins -1 (T and B lymphocytes), -7 (keratinocytes and 
carcinomas), -8 (carcinomas), -9 (thymocytes) and -12 (adipocytes) (reviewed in15). Galectin-9 (Gal9) was first 
described as a selective chemoattractant for eosinophils16, but is now known to have a wider function including as 
a urate transporter in the kidney17. Gal9 functions as a voltage-sensitive channel that mediates transport of urate, 
a product of purine metabolism that is elevated in the serum of individuals with renal dysfunction and associated 
with development of gout.
In the immune system Gal9 has been shown to regulate interactions between thymic epithelial cells and thy-
mocytes and promotes apoptosis of immature thymocytes when applied exogenously18. Similar to galectin-1, 
Gal9 induces cell death of mature activated T cells through caspase and calpain-dependent pathways19. The sur-
face receptor that is crucial for exogenous Gal9 function is TIM3 (T cell immunoglobulin- and mucin domain 
containing molecule) expressed on differentiated T helper cells20,21. Dysregulation of this signalling pathway has 
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been documented in autoimmune diseases such as multiple sclerosis22. Activation of the Gal9/TIM3 pathway has 
also been shown to be important in graft rejection23. In addition to pro-apoptotic activity, Gal9 induces differen-
tiation of naïve T cells into a regulatory phenotype while inhibiting their development into Th17 cells2 and stimu-
lates maturation of dendritic cells with production of Th1-type cytokines24. Gal9 has been shown to be expressed 
in RA synovium and it has been reported that a mutant form of Gal9 was able to induce apoptosis in synovial 
fibroblasts when added exogenously to cell cultures25. Furthermore, Gal9 was shown to have a beneficial effect on 
mouse collagen-induced arthritis when given exogenously25. However, it is clear that galectins often have different 
functions in the extracellular and intracellular context14,26 and the role of endogenous Gal9 in synovial fibroblasts 
and RA pathogenesis has not been established. With an emerging role for galectins in immune modulation and 
inflammatory diseases the present study examined galectin expression in the specific context of RA.
Results
Galectin 9 is differentially expressed in RA synovial tissue. Analysis of galectin expression by real 
time PCR in synovial fibroblasts and matched skin fibroblasts showed expression of Gal1, -3, -4, -8 and -9 in both 
synovial and dermal fibroblasts (Fig. 1). However, Gal9 was the only galectin that showed increased expression 
in the synovial compared to the dermal fibroblasts (p < 0.01). Immunofluorescence staining of synovial tissue 
sections from RA patients confirmed extensive Gal9 expression. Co-staining with the synovial fibroblast markers, 
podoplanin and fibroblast activation protein (FAP) demonstrated that Gal9 was expressed largely by fibroblasts 
(Fig. 2). Given these data, we focussed on the regulation and role of Gal9 in synovial fibroblasts.
Regulation of Gal9 expression. Toll-Like Receptor effects on Gal9 Expression. In order to assess which 
factors might modulate Gal9 expression we first considered whether toll-like receptor (TLR) activation could 
affect expression of Gal9. RA synovial fibroblasts were stimulated with the TLR ligands bLP, poly(I:C) and LPS. 
No significant effects on Gal9 mRNA expression were observed following stimulation with bLP, but stimulation 
Figure 1. Galectin expression was assessed in synovial and dermal fibroblasts from RA patients by real-time 
PCR. Data are mean ± SD and * indicates p < 0.05, n = 6.
Figure 2. Synovial membrane sections were stained for Podoplanin (green), FAP (red), galectin-9 (blue) and 
nuclei using DAPI (white). Co-localisation of podoplanin and galectin-9 can be seen as cyan, co-localisation of 
FAP and galectin-9 appears magenta. Scale bar 50 μm.
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with poly(I:C) (a TLR3 agonist) gave a significant (p < 0.01) 25-fold increase in Gal9 mRNA. LPS (a TLR4 ago-
nist) stimulation led to a smaller, but significant (p < 0.05) 10-fold increase in Gal9 mRNA (Fig. 3A). Thus, Gal9 
expression can be induced by activation of the TLR3 and TLR4 pathways. By contrast Gal3 expression could 
not be induced by any of the TLR ligands used here, suggesting some selectivity for TLR3 and TLR4 signalling 
towards induction of Gal9 (data not shown).
Figure 3. RA synovial fibroblasts were stimulated with (A) TLR agonists, TNFα, IL-1β, bLP, poly(I:C), LPS 
and (B) pro-inflammatory cytokines –IL-1β, IL-4, IL-6, IL-17, IFNγ, TNFα and TGFβ. mRNA was extracted 
and fold-changes were plotted. (C) The increase in Gal9 expression following IFNγ stimulation was confirmed 
at the protein level by Western blotting. Long (39 KDa) and short (35 KDa) isoforms of Gal9 are shown. The 
short isoform was induced by IFNγ stimulation whereas the long isoform is constitutively expressed. *p < 0.05, 
**p < 0.01. Full uncropped versions of the blots are shown in the supplementary data.
www.nature.com/scientificreports/
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Cytokine effects on Gal9 expression. The RA synovial environment contains many pro-inflammatory cytokines, 
including IL-1β, IL-4, IL-6, IL-17, IFNγ, TNFα and TGFβ which mediate different aspects of disease pathology. 
In order to determine whether they play a role in the upregulation of Gal9 expression, RA synovial fibroblasts 
and matched skin fibroblasts were stimulated with each of the aforementioned cytokines. Only IL-1β (4-fold) 
and IFNγ (35-fold) were found to induce significant (p < 0.05) increases in Gal9 mRNA expression (Fig. 3B). 
The effects of IFNγ were studied further with increases in Gal9 protein expression in synovial fibroblasts in 
response to IFNγ stimulation confirmed by Western blot (Fig. 3C, upper panel). Two isoforms of Gal9 exist -a 
long (39 KDa) and short (35 KDa) form. The long isoform was constitutively expressed in RA synovial fibroblasts 
and expression was increased in a time-dependent manor following IFNγ stimulation for 24–48 hours. However 
IFNγ stimulation induced a more profound effect on the short isoform, which was not readily detectable in 
untreated cells but was evident after 24 hours. Increased expression of the short isoform could be inhibited by an 
anti-IFNγ antibody (Fig. 3C, lower panel).
Effect of Galectin 9 Silencing on synovial fibroblasts. To determine whether the increased expression 
of Gal9 might affect synovial fibroblast proliferation and apoptosis RA synovial fibroblasts were transfected with 
Gal9 siRNA, or a scrambled siRNA (Scr) sequence and a control group of cells were left un-transfected. Effective 
silencing of Gal9 expression using RNA interference was confirmed by Western blotting (Fig. 4A). In order to 
assess whether knockdown of Gal9 affected fibroblast proliferation, XTT reduction to formazan was measured at 
48, 72 and 96 h post Gal9 siRNA transfection. Gal9 knockdown was shown to have no effect on fibroblast prolifer-
ation stimulated with TNFα and IL-1β (10 ng/ml each) (Fig. 4B). AnnexinV binds to phosphatidylserine exposed 
on the cell membranes of apoptotic cells. Staining with annexin V-FITC showed greater binding of annexin V 
to the Gal9 siRNA transfected population compared to the scr siRNA population (Fig. 3C), suggesting that loss 
of Gal9 leads to increased apoptosis in these cells. This finding was confirmed using JC-1 staining to measure 
mitochondrial membrane depolarisation as a second measure of apoptosis, (Fig. 4D), consistent with increased 
apoptosis after Gal9 knock down. The Gal9 siRNA transfected fibroblasts also displayed visual signs of cell death 
24 hours post-transfection with marked cell cytoplasm shrinkage, rounding up of cells and loss of classic fibro-
blast morphology (Fig. 5A).
Discussion
Galectins 1 and 3 have previously been described as mediators of inflammatory processes27–29 where they act as 
chemoattractants for neutrophils, and facilitate recognition and killing of bacteria in pathogen-mediated inflam-
mation10. In the present study we assessed galectin expression in fibroblasts from synovial tissue and matched 
non-inflamed skin of patients with RA and showed that expression of Gal9 was unique in being differentially 
increased in the synovial fibroblasts. Gal9 has been reported to be expressed at high levels within the RA syn-
ovium and previous reports have shown exogenous Gal9 to have a pro-apoptotic role within this tissue25. The 
very low level of Gal9 in skin fibroblasts in the present study suggests that the raised Gal9 could be a consequence 
of the local inflammatory environment. Fibroblasts play a central role in the “activated” synovium, recruitment 
of immune cells to the inflammatory milieu, and thus maintenance of persistent inflammation1,30. Their sur-
vival and proliferation within the inflamed joint may, therefore, represent a key early step in the transition to 
chronic inflammation. Knockdown of Gal9 by siRNA induced apoptosis in RA synovial fibroblasts, suggesting 
that endogenous Gal9, in contrast to exogenous Gal925, protects against rather than induces apoptosis.
The induction of apoptosis following siRNA knockdown of Gal9 compared with the pro-survival effects of 
exogenous Gal9 shown previously by Seki and colleagues25 indicates that endogenous and exogenous forms of 
Gal9 play opposing roles in regulating cell death. In the RA synovium, fibroblast populations are maintained, in 
part due to the cytokine and chemokine repertoire produced by the inflammatory milieu. We have demonstrated 
here that activation of the TLR3 and TLR4 pathways in synovial fibroblasts lead to increased protection from 
apoptosis of synovial fibroblasts through induction of Gal9 expression. TLR expression in the RA synovium 
has been well characterised31 and it is known that TLRs in concert with pattern recognition receptors (PPRs), in 
particular nucleotide-binding oligomerisation domain 2 (NOD-2) activate synovial fibroblasts and promote and 
maintain inflammatory mediator expression32.
In the current study, IFNγ was the most potent inducer of Gal9 expression (Fig. 3B). Additionally, our data 
suggest that an inflammatory environment containing IFNγ would profoundly upregulate the short isoform of 
Gal9. Therefore, it could be that this short isoform is of functional significance in protection of synovial fibro-
blasts against apoptosis during inflammation and may represent an important therapeutic target.
We have shown that endogenous Gal9 expression also maintains the fibroblast population through protection 
against apoptosis, and thus contributes directly to the maintenance of persistent inflammation within the RA 
joint. Understanding the endogenous and exogenous roles of Gal9 is integral to understanding how to manipu-
late it for use as a therapeutic target. Endogenous Gal9 has been implicated in prevention of malignant tumour 
progression through disruption of CD44-hyaluronan interactions33, acting as a potent IgE antagonist prevent-
ing degranulation of mast cells34 and as an inducer of immunosuppressive macrophages which ameliorate T 
cell-driven inflammation35. Exogenous Gal9, however, has been shown to induce apoptosis in synovial fibroblasts, 
T cells25,36 and other immune cell lineages18 to prevent Th17 differentiation2 and to reduce inflammation in pso-
riasis patients37. Unlike Gal3, Gal9 is largely intracellular in vivo due to its lack of a signal peptide for secretion38. 
There is currently no evidence that fibroblasts are able to secrete the Gal9 which they produce, unlike T cells 
which readily secrete it upon T cell receptor (TCR) stimulation39. Therefore, it is possible that intracellular Gal9 
effects may dominate extracellular Gal9 effects that are generated through cell surface receptors such as TIM3. 
The nature of Gal9 intracellular function could be similar to that observed for intracellular Gal3, which is known 
to interact with members of the anti-apoptotic Bcl-2 family40. There are, therefore, two possible means of exploit-
ing Gal9 as a therapeutic: firstly removing blockade of apoptosis through blockade of endogenous, intracellular 
www.nature.com/scientificreports/
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Gal9. Secondly, through administration of exogenous Gal9 which can signal through membrane bound receptors 
to induce apoptosis. We conclude that Gal9 represents an important and novel target for treatment of RA and 
potentially other auto-inflammatory diseases.
Methods
Galectin expression in synovial tissue and fibroblasts. RA synovial tissue was obtained from biopsies 
from RA patients recruited from Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals 
Birmingham NHS Foundation Trust UK. All patients fulfilled the 1987 ACR classification criteria for RA with 
symptom duration of greater than 3 months, were CCP+, RHF+ and underwent synovial biopsy of the knee. 
All patients provided written, informed consent (West Midlands Black Country Research Ethics Committee 
Approval 07/H1203/57). Frozen RA tissues were cut in 6 μm thick sections, fixed with acetone and frozen prior 
to use. Slides were washed in Phosphate Buffered Saline (PBS), incubated for 30 min in 10% Horse serum/PBS 
and incubated overnight at 4circC with primary antibodies to Galectin-9 (Abcam, Cambridge, UK), Fibroblast 
Figure 4. (A) Gal9 knock-down following siRNA transfection was confirmed by Western blotting. (B) Cell 
proliferation in the presence of TNFα and IL-1β (10 ng/ml of each) was shown to be unaffected by siRNA 
transfection. Data are mean ± SD. Apoptosis in each fibroblast population was measured by (C) annexin 
V staining and (D) JC-1 mitochondrial membrane depolarisation staining. *p < 0.05, ***p < 0.001. Full 
uncropped versions of the blots are shown in the supplementary data.
www.nature.com/scientificreports/
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Activation Protein, FAP (Invitrogen, Waltham, MA, USA, clone F11-24) and Podoplanin (Invitrogen, clone 
NZ-1.3). After washing with PBS, slides were incubated with secondary antibodies anti-mouse IgG1 Alexa 546 
(Life Technologies, Paisley, Scotland), anti-rabbit IgG Alexa 488 (Life Technologies) and anti-rat IgG Alexa 647 
(Jackson ImmunoResearch, Cambridge, UK) for 30 min, counterstained with DAPI (Life Technologies) and 
mounted in aqueous mounting media. Tissues were imaged using a Zeiss LSM 780 confocal microscope and 
processed using ZEN black (ZEISS, Cambridge, UK). Fibroblasts were isolated by explant culture from synovial 
tissue and skin from the same patients as previously described41 and grown to confluence to determine expression 
of galectins 1, 3, 4, 8 and 9 by real-time PCR. All patients provided written, informed consent (West Midlands 
Black Country Research Ethics Committee Approval 07/H1204/191).
Real-Time PCR. RNA was prepared using an RNeasy Mini Kit (Qiagen, Manchester, UK) and reverse tran-
scription was carried out using Superscript Vilo (Life Technologies, Paisley, UK) according to the manufactur-
er’s instructions. Real-time PCR was carried out using FAM-labelled TaqMan® Human Gene Expression assays 
for the galectins of interest as well as IL-1β, IL-4, IL-6, IL-17, IFNγ, TNFα, TGFβ and β-actin control (Life 
Technologies, Paisley, UK). All samples were analysed using a 7900HT real-time PCR machine (Life Technologies, 
Paisley, UK). Data were expressed as ΔΔCt values.
Cell stimulation. RA synovial fibroblasts were seeded into 24 well plates and incubated at 37 °C, 5% CO2 
until confluent. The culture medium was replaced with 500 μl fresh complete RPMI 1640 medium (10% FCS, 
400 μM L-glutamine, 2,000 U/ml penicillin, 2 mg/ml streptomycin, 1% v/v NEAA, 1% v/v sodium pyruvate, all 
from Sigma Aldrich, Gillingham, UK) prior to treatment with 10 ng/ml of each of the cytokines IL-1β, IL-17, 
IFNγ, TNFα, TGFβ, IL-4 (all R&D Systems, Abingdon, UK), or IL-6 (Peprotech, New Jersey, USA) (20 ng/ml), or 
TLR agonists 300 ng/ml bacterial lipoprotein (bLP; InvivoGen, San Diego, US), 10 μg/ml poly(I:C) (InvivoGen, 
San Diego, US), or 100 ng/ml LPS (List Biological Laboratories, Campbell, USA). The cells were incubated for 
24 hours at 37 °C, 5% CO2 after which RNA was extracted for Gal9 expression as determined by Real time PCR.
Western blotting. Synovial fibroblasts were washed with PBS and lysed with SDS loading buffer (0.125 M 
Tris pH 6.8, 20% glycerol, 2% SDS, 5% 2-mercaptoethanol and 25 mg/ml bromophenol blue). Lysates were then 
heated for 10 minutes at 100 °C. Samples were run on a 12% SDS-PAGE gel followed by transfer to PVDF mem-
brane. Gal9 was detected using an anti-Gal9 primary antibody (GalPharma) and anti-mouse secondary antibody 
(ThermoFisher, Uk). Blots were developed with ECL before transfer to x-ray film (Kodak). Densitometry was 
determined using ImageJ (NIH).
Galectin 9 silencing. Synovial fibroblasts at passage 3–6 were seeded into 6-well culture plates and incubated 
in complete RPMI 1640 at 37 °C to 50% confluence. Fibroblasts were transfected using Lipofectamine 2000 (Life 
Technologies, Paisley, UK) following the manufacturers protocol. siRNA was used at a final concentration of 
90 nM for both Scr and Gal9.
Figure 5. (A) Fibroblasts were visualised by light microscopy following transfection with scr siRNA, Gal9 
siRNA or treatment with Lipofectamine only (no RNAi control). Original magnification x40. Images are 
representative of 2 populations from a total of 5 primary RA synovial fibroblast populations observed. (B) 
Cell counts of n = 5 primary human synovial fibroblast populations in a 12-well plate following Gal9 siRNA 
transfection. Data are pooled from three separate experiments. Statistical significance was determined using a 
one-way ANOVA with Tukey post-hoc test.***p < 0.001.
www.nature.com/scientificreports/
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Fibroblast Proliferation Assay. Fibroblast proliferation was assessed using XTT (Cell Proliferation Kit; 
Biological Industries, Kibbutz Beit-Haemek, Israel) following Gal9 knockdown. XTT is reduced to formazan 
by live cells and the intensity of absorption at 450 nm is directly proportional to the number of live metaboli-
cally active cells present42. Fibroblasts were cultured in 96-well plates at a density of 8 × 104 cells/100 μl culture 
medium. As a positive control, fibroblasts were stimulated with 10 ng/ml TNFα and 10 ng/ml IL-1β. Cell pro-
liferation was assessed at 48, 72 and 96 h post-stimulation. XTT was prepared according to the manufacturer’s 
instructions and was added to the fibroblasts. Fibroblasts were incubated for 3 h in the presence of XTT at 37 °C 
and the plate was read at 450 nm with a reference wavelength of 620 nm.
Fibroblast Apoptosis Assays. Synovial fibroblast apoptosis was assessed using two methods, annexin V 
binding43 and JC-1 staining44. For Annexin V staining fibroblasts were trypsinised and resuspended in RPMI 
1640 and combined with the cell culture supernatants containing non-adherent dead cells and washed in PBS 
(300 xg, 5 minutes). The resulting pellet was resuspended in annexin V buffer (10 mM HEPES, pH7.4; 140 mM 
NaCl; 2.5 mM CaCl2) and stained with anti-annexin V-FITC and propidium iodide (PI) (eBioscience). Annexin 
V positive cells were detected using a CyAn ADP flow cytometer (Beckman Coulter, High Wycombe, UK).
For JC-1 staining fibroblasts were stained with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine 
iodide (JC-1) (Sigma Aldrich, Dorset, UK). In live cells, JC-1 exists in both its monomeric and aggregated forms 
which emit fluorescence at 530 nm (green) and 590 nm (red). In apoptosing or dead cells, only the monomeric 
form exists. RA synovial fibroblasts transfected with Gal9 siRNA, Scr siRNA and the control group were stained 
with JC-1 following the manufacturer’s instructions, and the shift from red to green fluorescence was measured 
using an Accuri C6 flow cytometer (Becton Dickinson, Oxford, UK).
Statistical Analysis. Non-parametric distribution was assumed for all assays. For comparison of two groups 
the Mann-Whitney U test was used. Analysis of Gal9 expression in multiple groups of fibroblasts was performed 
with Kruskal-Wallis one-way analysis of variance and Dunn’s post-test. All analyses were carried out using the 
Graphpad Prism 5 statistical software package.
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